Vir Biotechnology Inc.
Organization details
- Legal name
- Vir Biotechnology Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- VIR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001706431
- EIN
- 81-2730369
- Wikidata ID
- Q77083018
Board of directors
-
Backer Marianne De · Director · President and CEOSince 2024
-
Charles Elliott Sigal · DirectorSince 2023
-
George A. Scangos · Director · President and CEOSince 2023
-
Janet Napolitano · DirectorSince 2023
-
Jeffrey S. Hatfield · DirectorSince 2023
-
Norbert W. Bischofberger · DirectorSince 2024
-
Phillip A. Sharp · DirectorSince 2023
-
Ramy Farid · DirectorSince 2024
-
Robert J. More · DirectorSince 2023
-
Robert J. Perez · DirectorSince 2023
- Since 2023
-
Saira Ramasastry · DirectorSince 2023
-
Suzanne Louise Topalian · DirectorSince 2026
- Since 2026
-
Vicki L. Sato · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 25, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
55.3%
-
94.4%
Board connections
12 of this board's directors also sit on 24 other boards. 21 are in the same sector.
-
Alnylam Pharmaceuticals Inc. Same sectorvia Charles Elliott Sigal and Phillip A. Sharp
-
ADC Therapeutics SA Same sectorvia Timothy Coughlin
- via George A. Scangos
-
Allogene Therapeutics Inc. Same sectorvia Vicki L. Sato
-
Arrowhead Pharmaceuticals Inc. Same sectorvia Backer Marianne De
-
City Therapeutics Inc. Same sectorvia Robert Nelsen
-
Denali Therapeutics Inc. Same sectorvia Vicki L. Sato
-
Faeth Therapeutics Inc. Same sectorvia Saira Ramasastry
-
Fate Therapeutics Inc. Same sectorvia Timothy Coughlin
- via Janet Napolitano
-
Immunocore Holdings plc Same sectorvia Robert J. Perez
-
Kardigan Inc. Same sectorvia Robert Nelsen
-
Lyell Immunopharma Inc. Same sectorvia Robert Nelsen
-
Mirum Pharmaceuticals Inc. Same sectorvia Saira Ramasastry
-
Prime Medicine Inc. Same sectorvia Robert Nelsen
-
Rapport Therapeutics Inc. Same sectorvia Robert J. Perez
-
Sana Biotechnology Inc. Same sectorvia Robert Nelsen
-
Schrodinger Inc. Same sectorvia Ramy Farid
-
Structure Therapeutics Inc. Same sectorvia Ramy Farid
-
Travere Therapeutics Inc. Same sectorvia Timothy Coughlin
-
Tyra Biosciences Inc. Same sectorvia Robert J. More
-
Voyager Therapeutics Inc. Same sectorvia George A. Scangos
- via Janet Napolitano
-
aTyr Pharma Inc. Same sectorvia Timothy Coughlin
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $8,190,629
- 34 sales by 9 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 3, 2026 | de Verneuil Vanina Officer (EVP, General Counsel, Corp Sec) | Open-market sale | −2,407 | $11.10 | $26,718 |
| Nov 2, 2026 | de Verneuil Vanina Officer (EVP, General Counsel, Corp Sec) | Open-market sale | −1,343 | $11.33 | $15,222 |
| Oct 27, 2026 | Suzanne Louise Topalian Director | Grant or award | +8,000 | — | — |
| Oct 27, 2026 | Suzanne Louise Topalian Director | Grant or award | +4,731 | — | — |
| Aug 11, 2026 | Robert J. More Director | Other | −8,000 | — | — |
| Aug 11, 2026 | Robert J. More Director | Other | +8,000 | — | — |
| Jun 9, 2026 | Timothy Coughlin Director | Grant or award | +8,000 | — | — |
| Jun 9, 2026 | Timothy Coughlin Director | Grant or award | +8,000 | — | — |
| Jun 1, 2026 | Janet Napolitano Director | Open-market sale | −3,200 | $9.45 | $30,240 |
| Jun 1, 2026 | Sabatini Brent Officer (SVP, Chief Accounting Officer) | Open-market sale | −379 | $9.45 | $3,582 |
| May 27, 2026 | Charles Elliott Sigal Director | Grant or award | +8,000 | — | — |
| May 27, 2026 | Janet Napolitano Director | Grant or award | +8,000 | — | — |
| May 27, 2026 | Robert J. More Director | Grant or award | +8,000 | — | — |
| May 27, 2026 | Jeffrey S. Hatfield Director | Grant or award | +8,000 | — | — |
| May 27, 2026 | Ramy Farid Director | Grant or award | +8,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Vir Biotechnology Inc.
Who is the CEO of Vir Biotechnology Inc.?
George A. Scangos has been Vir Biotechnology Inc.'s President and CEO since January 2017.
How many directors are on Vir Biotechnology Inc.'s board?
Vir Biotechnology Inc.'s board has 15 directors: Backer Marianne De, Charles Elliott Sigal, George A. Scangos, Janet Napolitano, Jeffrey S. Hatfield, Norbert W. Bischofberger, Phillip A. Sharp, Ramy Farid, Robert J. More, Robert J. Perez and 5 others.
Are Vir Biotechnology Inc. insiders buying or selling shares?
Over the last 12 months, Vir Biotechnology Inc. insiders made no open-market purchases and sold $8.2 million of shares in 34 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="vir-biotechnology-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.